Use of a Novel Study Insight Analytics (SIA) Methodology to Improve PANSS Data Quality and Signal Detection in a Global Clinical Trial in Schizophrenia

Authors

M Opler, WCG Inc., New York, NY, USA. Electronic address: mark.opler@panss.org.
S Negash, WCG Inc., New York, NY, USA.
K Tatsumi, WCG Inc., New York, NY, USA.
C Liu, WCG Inc., New York, NY, USA.
M Komaroff, Noven Pharmaceuticals, Inc., Jersey City, NJ, USA.
G Capodilupo, WCG Inc., New York, NY, USA.
M Hasebe, Hisamitsu Pharmaceutical Co., Inc., Tosu, Japan.
B Echevarria, WCG Inc., New York, NY, USA.
R Blattner, WCG Inc., New York, NY, USA.
L Citrome, New York Medical College, New York, NY, USA.

Author Type(s)

Faculty

Journal Title

Schizophrenia Research

First Page

239

Last Page

246

Document Type

Article

Publication Date

5-1-2024

Department

Psychiatry and Behavioral Sciences

Recommended Citation

Opler, M., Negash, S., Tatsumi, K., Liu, C., Komaroff, M., Capodilupo, G., Hasebe, M., Echevarria, B., Blattner, R., & Citrome, L. (2024). Use of a Novel Study Insight Analytics (SIA) Methodology to Improve PANSS Data Quality and Signal Detection in a Global Clinical Trial in Schizophrenia. Schizophrenia Research, 267, 239-246. https://doi.org/10.1016/j.schres.2024.03.052